Share on LinkedInShare on LinkedIn

ARTICLE · 14 FEBRUARY 2020

Pharmaceutical Price Fixing Prosecutions Offer Guidance On Interactions With Competitors

Earlier this month, the Department of Justice (DOJ) announced yet another case filed in the Eastern District of Pennsylvania...

United StatesAntitrust/Competition Law

Earlier this month, the Department of Justice (DOJ) announced yet another case filed in the Eastern District of Pennsylvania against a former pharmaceutical executive for allegedly conspiring to fix prices for generic drugs. U.S. Attorney William McSwain touted the enforcement action as the third of its kind within the last year, following similar antitrust cases filed against Rising Pharmaceuticals and Heritage Pharmaceuticals. The action and statements from DOJ officials serve as notice to the generic pharmaceutical industry and its participants that the ongoing criminal investigation—which reportedly dates back to 2014 and has spawned a number of collateral civil suits—will continue to target conduct within the pharmaceutical industry that it alleges violates antitrust laws. The indictment also demonstrates the DOJ will seek to hold senior executives individually accountable for conduct the government believes violates the antitrust laws.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from